Exploring the neurobiological mechanisms of ketamine, psychedelics, and other rapid antidepressants
Explore the archives below.
January 23, 2023
NOTE date
Victoria DeLeon (WashU Psychiatry)
“Ketamine and Nitrous Oxide for Acute Suicidality”
Papers to review:
- “Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I)” Journal of Clinical Psychiatry (2020)
- “Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)” Journal of Clinical Psychiatry (2021)
February 27, 2023
Rescheduled from February 20
Charles Zorumski (WashU Psychiatry)
Topic: New initiative to fund antidepressants research at WashU through the Taylor Foundation
Below are two papers that have just come out that may be of interest to you.
- Vargas, et al. Psychedelics promote neuroplasticity throughthe activation of intracellular 5-HT2A receptors. Science 379, 700–706 (2023)
- Zanos, et al. NMDA Receptor Activation-Dependent AntidepressantRelevant Behavioral and Synaptic Actions of Ketamine. The Journal of Neuroscience, February 8, 2023 • 43(6):1038–1050
March 20, 2023
Manoj Doss (Johns Hopkins University)
“Cinco Sins of Psychedelic Science”
April 17, 2023
Alex Kwan (Cornell University)
“Visualizing drug actions on dendrites: From ketamine to psilocybin”
May 15, 2023
Charles Conway (WashU Psychiatry)
“A Phase II trial of Nitrous Oxide for TRD”
June 26, 2023
NOTE date
Candace Lewis (Arizona State University)
“Harnessing the malleable epigenome in the pursuit of healing”
September 18, 2023
Joshua Siegel (WashU Psychiatry)
October 16, 2023
Lindsay Cameron (Stanford University)
November 20, 2023
John McCorvy (Medical College of Wisconsin)
December 18, 2023
Boris Heifets (Stanford University)
July 18, 2022
Amelia Christensen (Kepecs lab, WashU Neuroscience)
“Interactions between psychedelic agonism of 5ht2a receptors and dopamine dependent reinforcement learning”
August 15, 2022
NOTE 3:00p start time
Rick Reneau (Braver lab, WashU Psychological & Brain Sciences)
“Imaging the effect of ketamine on synaptic density (SV2A) in the living brain” Molecular Psychiatry (2022)
September 19, 2022
Oliver Krentzman (Kepecs lab, WashU Neuroscience)
“Oxytocin-dependent reopening of a social reward learning critical period with MDMA” (Nature 2019)
October 17, 2022
Peter Lambert (Mennerick lab, WashU Psychiatry)
“Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2” (Neuron 2022)
November 21, 2022
Joshua Siegel (Nicol lab, WashU Psychiatry)
Jonah Padawer-Curry (Bauer lab, WashU Radiology)
WiP: “Neural and neurovascular effects of 5-HT2A receptor modulation (psychedelic, non-psychedelic agonism, and antagonism)”